Advertisement

EnteroMedics closes a $13 million public offering it plans to use to win FDA approval for its Maestro weight loss device.

MassDevice.com Wall Street Beat

EnteroMedics (NSDQ:ETRM) said it closed a public offering it expects to add about $12 million to its coffers after it pays off expenses.

The St. Paul, Minn.-based medical device company is developing technology to treat obesity using neurostimulation of the vagus nerve to suppress the appetite.

EnteroMedics said it plans to use the cash to pursue FDA approval of its Maestro RC vagal nerve blocking system and to commercialize the device overseas.

Advertisement
Advertisement